| . | Jasplakinolide . | LatA . | LY . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| . | Lifetime . | CME productivity . | CCS stabilized . | Lifetime . | CME productivity . | CCS stabilized . | Lifetime . | CME productivity . | CCS stabilized . |
| hESCs | + | + | No effect | − | − | + | − | No effect | + |
| NPCs | No effect | − | +++ | − | − | + | − | − | + |
| Fibroblasts | No effect | No effect | +++ | − | + | + | − | + | No effect |
| . | Jasplakinolide . | LatA . | LY . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| . | Lifetime . | CME productivity . | CCS stabilized . | Lifetime . | CME productivity . | CCS stabilized . | Lifetime . | CME productivity . | CCS stabilized . |
| hESCs | + | + | No effect | − | − | + | − | No effect | + |
| NPCs | No effect | − | +++ | − | − | + | − | − | + |
| Fibroblasts | No effect | No effect | +++ | − | + | + | − | + | No effect |
Table summarizes the different effect of actin and PI-3 kinase drugs on CME of the three cell types. + and – indicate, respectively, an increase or a decrease of the corresponding parameters compared to control condition.